Multiple endocrine neoplasia type 1 risk factors

Revision as of 12:05, 12 August 2019 by Mmir (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Multiple endocrine neoplasia type 1 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 1 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple endocrine neoplasia type 1 risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 1 risk factors

CDC on Multiple endocrine neoplasia type 1 risk factors

Multiple endocrine neoplasia type 1 risk factors in the news

Blogs on Multiple endocrine neoplasia type 1 risk factors

Directions to Hospitals Treating Multiple endocrine neoplasia type 1

Risk calculators and risk factors for Multiple endocrine neoplasia type 1 risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Common risk factors in the development of multiple endocrine neoplasia type-1 are family history, history of Zollinger-Ellison syndrome and pituitary dysfunction.

Risk Factors

Common risk factors in the development of multiple endocrine neoplasia type-1 include: [1]

References

  1. de Laat JM, Tham E, Pieterman CR, Vriens MR, Dorresteijn JA, Bots ML; et al. (2012). "Predicting the risk of multiple endocrine neoplasia type 1 for patients with commonly occurring endocrine tumors". Eur J Endocrinol. 167 (2): 181–7. doi:10.1530/EJE-12-0210. PMID 22581216.
  2. Kaiwar C, Macklin SK, Gass JM, Jackson J, Klee EW, Hines SL; et al. (2017). "Late onset asymptomatic pancreatic neuroendocrine tumor - A case report on the phenotypic expansion for MEN1". Hered Cancer Clin Pract. 15: 10. doi:10.1186/s13053-017-0070-0. PMC 5521080. PMID 28736585.
  3. Gibril F, Schumann M, Pace A, Jensen RT (2004). "Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature". Medicine (Baltimore). 83 (1): 43–83. doi:10.1097/01.md.0000112297.72510.32. PMID 14747767.
  4. Lee NE, Lee YJ, Yun SH, Lee JU, Park MS, Kim JK; et al. (2013). "A case of Zollinger-Ellison syndrome in multiple endocrine neoplasia type 1 with urolithiasis as the initial presentation". Korean J Gastroenterol. 61 (6): 333–7. PMID 23877214.
  5. Uraki S, Ariyasu H, Doi A, Furuta H, Nishi M, Usui T; et al. (2017). "Hypersecretion of ACTH and PRL from pituitary adenoma in MEN1, adequately managed by medical therapy". Endocrinol Diabetes Metab Case Rep. 2017. doi:10.1530/EDM-17-0027. PMC 5404709. PMID 28458907.
  6. Bonenti G, Corsino G (1969). "[Serum betalysine in dystrophic subjects]". Minerva Pediatr. 21 (34): 1557–60. PMID 5404709.

Template:WS Template:WH